{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:51:27Z","timestamp":1785891087617,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012465","name":"Zunyi Medical College","doi-asserted-by":"publisher","award":["YJSKYJJ2025066"],"award-info":[{"award-number":["YJSKYJJ2025066"]}],"id":[{"id":"10.13039\/501100012465","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.neuroscience.2026.06.009","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T18:05:12Z","timestamp":1781460312000},"page":"189-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Current status and challenges in targeting circulating amyloid-\u03b2 carriers for Alzheimer\u2019s disease therapy"],"prefix":"10.1016","volume":"610","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3956-7125","authenticated-orcid":false,"given":"Li","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei-Yue","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.neuroscience.2026.06.009_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252010964","article-title":"Pathology of amyloid-\u03b2 (A\u03b2) peptide peripheral clearance in Alzheimer's disease [J]","volume":"25","author":"Tsoy","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.06.009_b0010","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.4103\/1673-5374.335829","article-title":"The relationship between amyloid-beta and brain capillary endothelial cells in Alzheimer's disease [J]","volume":"17","author":"Zhang","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.06.009_b0015","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/1073858410381532","article-title":"Sink hypothesis and therapeutic strategies for attenuating Abeta levels [J]","volume":"17","author":"Zhang","year":"2011","journal-title":"Neuroscientist"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0020","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2575110","article-title":"The role of neutrophils, red blood cells, and platelets in the pathology of Alzheimer's disease [J]","volume":"57","author":"Xu","year":"2025","journal-title":"Ann. Med."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.06.009_b0025","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.bpj.2013.08.025","article-title":"Mapping the interactions between the Alzheimer's A\u03b2-peptide and human serum albumin beyond domain resolution [J]","volume":"105","author":"Algamal","year":"2013","journal-title":"Biophys. J ."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.140367","article-title":"Amyloid capture and aggregation inhibition by human serum albumin [J]","volume":"301","author":"Cora","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pharmthera.2012.07.008","article-title":"Low-density lipoprotein receptor-related protein 1: a physiological A\u03b2 homeostatic mechanism with multiple therapeutic opportunities [J]","volume":"136","author":"Sagare","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0040","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1750-1326-4-17","article-title":"LRP1 shedding in human brain: roles of ADAM10 and ADAM17 [J]","volume":"4","author":"Liu","year":"2009","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0045","article-title":"LRP1 at the crossroads of A\u03b2 clearance and therapeutic targeting in Alzheimer's disease [J]","volume":"17","author":"Deng","year":"2025","journal-title":"Front. Aging Neurosci."},{"issue":"15","key":"10.1016\/j.neuroscience.2026.06.009_b0050","doi-asserted-by":"crossref","first-page":"13338","DOI":"10.1074\/jbc.M106792200","article-title":"Distinct binding sites in the structure of alpha 2-macroglobulin mediate the interaction with beta-amyloid peptide and growth factors [J]","volume":"277","author":"Mettenburg","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.06.009_b0055","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s12035-024-04442-8","article-title":"Tetrameric transthyretin as a protective factor against Alzheimer's disease [J]","volume":"62","author":"Corino","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0060","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies [J]","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol. Neurodegener."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.06.009_b0065","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006312","article-title":"Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease [J]","volume":"2","author":"Holtzman","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"12","key":"10.1016\/j.neuroscience.2026.06.009_b0070","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1172\/JCI36663","article-title":"apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain [J]","volume":"118","author":"Deane","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.neuroscience.2026.06.009_b0075","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26031380","article-title":"Molecular simulation of the binding of amyloid beta to apolipoprotein A-I in high-density lipoproteins [J]","volume":"26","author":"Malajczuk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3389\/fnins.2019.00419","article-title":"The extent of human apolipoprotein a-i lipidation strongly affects the \u03b2-amyloid efflux across the blood-brain barrier in vitro [J]","volume":"13","author":"dal Magro","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3389\/fnins.2019.00164","article-title":"Clusterin in Alzheimer's disease: mechanisms, genetics, and lessons from other pathologies [J]","volume":"13","author":"Foster","year":"2019","journal-title":"Front. Neurosci."},{"issue":"23","key":"10.1016\/j.neuroscience.2026.06.009_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262311361","article-title":"Amyloid \u03b2 peptide modifies membrane architecture and surface electrostatic properties of human red blood cells [J]","volume":"26","author":"Staneva","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0095","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1038\/s41467-024-52396-1","article-title":"Clearance and transport of amyloid \u03b2 by peripheral monocytes correlate with Alzheimer's disease progression [J]","volume":"15","author":"Huang","year":"2024","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.06.009_b0100","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14402","article-title":"Roles of blood monocytes carrying TREM2(R47H) mutation in pathogenesis of Alzheimer's disease and its therapeutic potential in APP\/PS1 mice [J]","volume":"21","author":"Yu","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"429","key":"10.1016\/j.neuroscience.2026.06.009_b0105","doi-asserted-by":"crossref","first-page":"ra52","DOI":"10.1126\/scisignal.aaf6240","article-title":"Platelets contribute to amyloid-\u03b2 aggregation in cerebral vessels through integrin \u03b1IIb\u03b23-induced outside-in signaling and clusterin release [J]","volume":"9","author":"Donner","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2024.114683","article-title":"Potential links between platelets and amyloid-\u03b2 in the pathogenesis of Alzheimer's disease: evidence from in vitro, in vivo, and clinical studies [J]","volume":"374","author":"Yubolphan","year":"2024","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.06.009_b0115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14283\/jpad.2018.48","article-title":"Cross-sectional characterization of albumin glycation state in cerebrospinal fluid and plasma from Alzheimer's disease patients [J]","volume":"6","author":"Costa","year":"2019","journal-title":"J. Prev Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/13872877251375430","article-title":"A real-world study on the safety and efficacy of therapeutic plasma exchange in patients with Alzheimer's disease [J]","volume":"108","author":"Taragano","year":"2025","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.neuroscience.2026.06.009_b0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14737175.2021.1960823","article-title":"Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease [J]","volume":"21","author":"Boada","year":"2021","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0130","article-title":"The use of plasma exchange with albumin replacement in the management of Alzheimer's disease: a scoping review [J]","volume":"15","author":"Cantero-Fortiz","year":"2024","journal-title":"Front. Neurol."},{"issue":"5","key":"10.1016\/j.neuroscience.2026.06.009_b0135","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1021\/acs.bioconjchem.9b00209","article-title":"Modification of serum albumin by high conversion of carboxyl to amino groups creates a potent inhibitor of amyloid \u03b2-protein fibrillogenesis [J]","volume":"30","author":"Wang","year":"2019","journal-title":"Bioconjug. Chem."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.06.009_b0140","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/acschemneuro.7b00128","article-title":"Iminodiacetic acid-modified human serum albumin: a multifunctional agent against metal-associated amyloid \u03b2-protein aggregation and cytotoxicity [J]","volume":"8","author":"Xie","year":"2017","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0145","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jinorgbio.2017.03.009","article-title":"Modulation effect of acidulated human serum albumin on Cu(2+)-mediated amyloid \u03b2-protein aggregation and cytotoxicity under a mildly acidic condition [J]","volume":"171","author":"Xie","year":"2017","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2024.113753","article-title":"Covalent immobilization of human serum albumin on cellulose acetate membrane for scavenging amyloid beta - a stepping extracorporeal strategy for ameliorating Alzheimer's disease [J]","volume":"234","author":"Ullah","year":"2024","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"4","key":"10.1016\/j.neuroscience.2026.06.009_b0155","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1039\/D1CB00067E","article-title":"Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies [J]","volume":"2","author":"Lundahl","year":"2021","journal-title":"RSC Chem. Biol."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.06.009_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116168","article-title":"Ibuprofen favors binding of amyloid-\u03b2 peptide to its depot, serum albumin [J]","volume":"23","author":"Litus","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117969","article-title":"Influence of Ibuprofen on glycerophospholipids and sphingolipids in context of Alzheime\u0155s disease [J]","volume":"185","author":"Radermacher","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.neuroscience.2026.06.009_b0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115896","article-title":"Serotonin promotes serum albumin interaction with the monomeric amyloid \u03b2 peptide [J]","volume":"22","author":"Litus","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.06.009_b0175","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bpj.2018.11.3133","article-title":"Fatty acids compete with A\u03b2 in binding to serum albumin by quenching its conformational flexibility [J]","volume":"116","author":"Guo","year":"2019","journal-title":"Biophys. J ."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.06.009_b0180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s10571-008-9339-1","article-title":"17beta-estradiol induces transthyretin expression in murine choroid plexus via an oestrogen receptor dependent pathway [J]","volume":"29","author":"Quintela","year":"2009","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnagi.2014.00235","article-title":"Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease [J]","volume":"6","author":"Nalivaeva","year":"2014","journal-title":"Front. Aging Neurosci."},{"issue":"2","key":"10.1016\/j.neuroscience.2026.06.009_b0190","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3233\/JAD-131355","article-title":"Transthyretin stabilization by iododiflunisal promotes amyloid-\u03b2 peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model [J]","volume":"39","author":"Ribeiro","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"22","key":"10.1016\/j.neuroscience.2026.06.009_b0195","doi-asserted-by":"crossref","first-page":"15511","DOI":"10.1021\/acs.jmedchem.3c01698","article-title":"Resveratrol derivatives inhibit transthyretin fibrillization: structural insights into the interactions between resveratrol derivatives and transthyretin [J]","volume":"66","author":"Yokoyama","year":"2023","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuroscience.2026.06.009_b0200","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s11010-024-05071-4","article-title":"The role of estrogen in Alzheimer's disease pathogenesis and therapeutic potential in women [J]","volume":"480","author":"Wang","year":"2025","journal-title":"Mol. Cell. Biochem."},{"issue":"14","key":"10.1016\/j.neuroscience.2026.06.009_b0205","doi-asserted-by":"crossref","first-page":"14171","DOI":"10.1021\/acs.jmedchem.5c01677","article-title":"Advancements in hydrazide-based HDAC inhibitors: a review of recent developments and therapeutic potential [J]","volume":"68","author":"Raucci","year":"2025","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.06.009_b0210","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/cmdc.201800031","article-title":"Transthyretin mimetics as anti-\u03b2-amyloid agents: a\u2009comparison of peptide and protein approaches [J]","volume":"13","author":"Pate","year":"2018","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0215","doi-asserted-by":"crossref","first-page":"13744","DOI":"10.1038\/s41598-018-31808-5","article-title":"Copper mediated amyloid-\u03b2 binding to transthyretin [J]","volume":"8","author":"Ciccone","year":"2018","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.neuroscience.2026.06.009_b0220","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1039\/D4SC08771B","article-title":"Zn(ii)-driven impact of monomeric transthyretin on amyloid-\u03b2 amyloidogenesis [J]","volume":"16","author":"Yi","year":"2025","journal-title":"Chem. Sci."},{"issue":"9","key":"10.1016\/j.neuroscience.2026.06.009_b0225","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/nm1635","article-title":"Clearance of amyloid-beta by circulating lipoprotein receptors [J]","volume":"13","author":"Sagare","year":"2007","journal-title":"Nat. Med."},{"issue":"21","key":"10.1016\/j.neuroscience.2026.06.009_b0230","doi-asserted-by":"crossref","first-page":"15154","DOI":"10.1074\/jbc.M112.439570","article-title":"A lipoprotein receptor cluster IV mutant preferentially binds amyloid-\u03b2 and regulates its clearance from the mouse brain [J]","volume":"288","author":"Sagare","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.neuroscience.2026.06.009_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158185","article-title":"indomethacin disrupts the formation of \u03b2-Amyloid plaques via an \u03b12-macroglobulin-activating lrp1-dependent mechanism [J]","volume":"22","author":"Guan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0240","article-title":"Novel heterozygous mutation in alpha-2-macroglobulin (A2M) suppressing the binding of amyloid-\u03b2 (A\u03b2) [J]","volume":"13","author":"Qiu","year":"2022","journal-title":"Front. Neurol."},{"issue":"15","key":"10.1016\/j.neuroscience.2026.06.009_b0245","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1111\/bph.16065","article-title":"Therapeutic effect of human ApoA-I-Milano variant in aged transgenic mouse model of Alzheimer's disease [J]","volume":"180","author":"Sol\u00e9","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1476-511X-10-8","article-title":"Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet [J]","volume":"10","author":"Song","year":"2011","journal-title":"Lipids Health Dis."},{"issue":"17","key":"10.1016\/j.neuroscience.2026.06.009_b0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176336","article-title":"ApoE lipidation as a therapeutic target in Alzheimer's disease [J]","volume":"21","author":"Lanfranco","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.neuroscience.2026.06.009_b0260","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1007\/s10571-023-01365-1","article-title":"Roles of ApoE4 on the pathogenesis in Alzheimer's disease and the potential therapeutic approaches [J]","volume":"43","author":"Sun","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0265","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13195-019-0498-8","article-title":"Peripheral administration of human recombinant ApoJ\/clusterin modulates brain beta-amyloid levels in APP23 mice [J]","volume":"11","author":"de Retana","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.neuroscience.2026.06.009_b0270","doi-asserted-by":"crossref","first-page":"14637","DOI":"10.1038\/s41598-017-15215-w","article-title":"Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral \u03b2-amyloidosis [J]","volume":"7","author":"Fern\u00e1ndez-De-Retana","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.06.009_b0275","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jconrel.2023.12.030","article-title":"Erythrocyte membrane-coated nanocarriers modified by TGN for Alzheimer's disease [J]","volume":"366","author":"Gu","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.06.009_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102874","article-title":"Platelets: a new therapeutic target for neurological diseases [J]","volume":"112","author":"Wei","year":"2025","journal-title":"Ageing Res. Rev."}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226003842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226003842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:20:49Z","timestamp":1785889249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226003842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S0306452226003842"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.06.009","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and challenges in targeting circulating amyloid-\u03b2 carriers for Alzheimer\u2019s disease therapy","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}